首页> 外文OA文献 >Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model

【2h】

Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model

机译：标准或药物遗传学指导管理下的达比加群与华法林预防房颤患者中风和全身血栓栓塞的发生：采用分析决策模型的成本/效用分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model [J] . Léon Nshimyumukiza, Julie Duplantie, Mathieu Gagnon, Thrombosis Journal . 2013,第1期

机译：标准或药物遗传学指导管理下的达比加群与华法林预防房颤患者中风和全身血栓栓塞的发生：采用分析决策模型的成本/效用分析
2. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: A cost-effectiveness analysis [J] . YouJ.H.S. Pharmacogenetics and genomics . 2014,第1期

机译：华法林与新型口服抗凝药在药物遗传学指导下预防房颤患者的中风：成本-效果分析
3. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: A cost-effectiveness analysis [J] . YouJ.H.S. Pharmacogenetics and genomics . 2014,第1期

机译：患有心房颤动患者中风预防的华法林与新型口腔抗凝血剂的药物发生的选择：成本效益分析
4. Group-Based Trajectory Analysis for Long-Term Use of Warfarin Therapy in Atrial Fibrillation Patients [C] . Shijing Guo, Xiang Li, Xin Du, MEDINFO . 2017

机译：基于组的术语轨迹分析，用于高级患者的华法林治疗
5. Dabigatran versus warfarin for the prevention of stroke in patients with chronic nonvalvular atrial fibrillation. [D] . Qiu, Fen. 2011

机译：达比加群与华法林预防慢性非瓣膜性房颤患者的中风。
6. Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model [O] . Léon Nshimyumukiza, Julie Duplantie, Mathieu Gagnon, 2013

机译：标准或药物遗传学指导管理下的达比加群与华法林预防房颤患者中风和全身血栓栓塞的发生：采用分析决策模型的成本/效用分析
7. Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation [O] . You, Joyce H. S., Tsui, Kia K. N., Wong, Raymond S. M., 2012

机译：达比加群与华法林基因型指导治疗房颤患者卒中预防的成本效果比较

Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model

著录项

相似文献

相关主题

期刊订阅